Kyntra Bio (KYNB) investor relations material

Executive summary

• Advanced clinical progress for FG-3246 (CD46-targeting ADC) and companion PET agent FG-3180 in metastatic castration-resistant prostate cancer (mCRPC), with Phase 2 trial actively enrolling and interim analysis expected in Q4 2026.

• Roxadustat program for anemia in lower-risk myelodysplastic syndromes (MDS) finalized Phase 3 protocol, targeting trial initiation in Q4 2026 and received Orphan Drug Designation from the FDA.

• Net income from continuing operations reached $12.0 million for Q2 2026, reversing a net loss of $13.7 million year-over-year, driven by a $30.9 million gain on deconsolidation of a European subsidiary.

• Cash runway extends into 2028, supporting continued investment in pipeline programs.

• Rebranded to Kyntra Bio, Inc. in January 2026, focusing on oncology and rare disease assets, with a Nasdaq symbol change to KYNB.

Financial highlights

• Q2 2026 total revenue was $(1.5) million, down from $1.3 million in Q2 2025, primarily due to negative drug product revenue adjustments.

• Operating costs and expenses rose to $16.1 million from $13.4 million year-over-year, mainly due to higher legal and clinical trial expenses.

• R&D expenses increased to $6.8 million from $5.9 million; SG&A expenses rose to $9.3 million from $7.1 million.

• Cash, equivalents, investments, and receivables totaled $95.7 million as of June 30, 2026.

• Net income from continuing operations was $12.0 million ($2.96 per share), compared to a net loss of $13.7 million ($3.38 per share) in Q2 2025.

Outlook and guidance

• Interim analysis for FG-3246 Phase 2 trial and initiation of pivotal Phase 3 roxadustat trial both targeted for Q4 2026.

• Cash and equivalents expected to fund operations into 2028.

• Expect continued losses as R&D expenses remain significant; additional funding may be required for future operations.